'Clinical endpoints' presentation slideshows

HIV Treatment and Clinical Trials 2014

HIV Treatment and Clinical Trials 2014. Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA. Disclosures Grants Bristol Myers Squibb, Gilead, Merck, ViiV

1k views • 77 slides

GI ASCO 2012 Non-colon update

960 views • 76 slides

HIV Treatment and Clinical Trials

HIV Treatment and Clinical Trials. Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA. Overview. Pathogenesis Testing Treatment When to start What to start When to switch Treatment as prevention

1.08k views • 76 slides

End points in IBD treatment Mucosal healing Vs Symptom relief

End points in IBD treatment Mucosal healing Vs Symptom relief. Jose Francis Lakeshore Hospital Kochi. Introduction. No cure for IBD No end points available!!. Treatment goals. * Maintenance of remission * Maintenance of QOL. * SYMPTOM RELIEF. Additional goals!!.

527 views • 42 slides

Design Issues in ABS Trials: Surrogates Endpoints & Non-Inferiority Trials October 29, 2003

FDA Anti-Infective Drugs Advisory Committee. Design Issues in ABS Trials: Surrogates Endpoints & Non-Inferiority Trials October 29, 2003 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of Washington. Design Issues in ABS Trials. Criteria for Study Endpoints

492 views • 28 slides

Statistical Evaluation of Surrogate Markers: Validity, Efficiency and Sensitivity

University of Pennsylvania Annual Conference on Statistical Issues in Clinical Trials. Statistical Evaluation of Surrogate Markers: Validity, Efficiency and Sensitivity. Yongming Qu, PhD Eli Lilly and Company Indianapolis, Indiana . April 18, 2012.

653 views • 27 slides

Bernard Chevalier, Jean Fajadet on behalf of the CRISTAL investigators

CRISTAL: A Prospective Randomized Trial of Sirolimus-Eluting Stents Compared to Balloon Angioplasty for Restenosis of Drug-Eluting Coronary Stents. Bernard Chevalier, Jean Fajadet on behalf of the CRISTAL investigators.

511 views • 24 slides

Key regulatory issues in the development of pharmabiotics in Europe

Key regulatory issues in the development of pharmabiotics in Europe. Valencia, November 5 th 2015. Biopolis is active in functional evaluation and infant nutrition as a developer of probiotics & oligosaccharides. Probiotics. Evaluation. Functional ingredients.

207 views • 18 slides

INCLUSION/EXCLUSION CRITERIA

INCLUSION/EXCLUSION CRITERIA. 1. The following are considerations when defining the cardiac arrest trial patient population (i.e., the inclusion/exclusion criteria): The defined trial population can support a reasonable enrollment rate;

836 views • 14 slides